Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 3 March 2025, 14:41 HKT/SGT
Share:
    

Source: Eisai
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine -

TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink “Chocola BB® Nightwell” (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. The productbelongs to the Chocola BB brand, which supports people’s beauty and health, and will be available at pharmacy and drugstores throughout Japan.

Chocola BB Nightwell contains eight active ingredients, including vitamin B2, which supports fatmetabolism and converts it into energy, and glycine, which improves sleep quality associated with poornutrition, as well as herbal medicines (Crataegus oxyacantha and Citrus unshiu peel). With a grapefruit flavor, Chocola BB Nightwell is easy to drink, low in calories (5.1 kcal per bottle), and caffeine-free, allowing consumption before bedtime. By promoting fatigue recovery during sleep, Chocola BB Nightwell supports a refreshed start to the day.

Since the launch of Chocola BB tablets in 1952, the Chocola BB brand has been offering products forover 70 years to address various skin and fatigue symptoms, in line with the needs of each era. The current Chocola BB drink lineup consists of designated quasi-drugs for fatigue care, including “ChocolaBB® Light” for daily fatigue, “Chocola BB® Royal 2” for severe fatigue, and “Chocola BB® Hyper” for low vitality.

By marketing the Chocola BB series of products, Eisai is committed to addressing the diverse needswithin fatigue care, and supporting the beauty and wellness of even more people.

Please refer to the product’s website for details about Chocola BB Nightwell (Japanese only) www.eisai.jp/products/chocola/chocola_bb_nightwell

FOr more information, visit https://www.eisai.com/news/2025/news202514.html

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: